Autoimmune and autoinflammatory rheumatic disorders (ARD) are treated with antimetabolites, calcineurin inhibitors and biologic agents either neutralizing cytokines [Tumor Necrosis Factor (TNF), Interleukin (IL)-1, IL-6, IL-17, B-cell activating factor] or being directed against B-cells (anti-CD-20), costimulatory molecules or JAK kinases. Similarly for the influenza or pneumococcal vaccines, there is limited data on the effectiveness of vaccination against SARS-CoV-2 infection and COVID-19 prevention for this susceptible patient population. Moreover, preliminary data from vaccinated organ transplanted, inflammatory bowel and connective tissue disease patients suggests only limited immunogenicity after the first vaccine dose, particularly in patients on immunosuppressive regimens. Herein a set of recommendations for the vaccination of immune suppressed patients with the SARS-CoV-2 vaccines is proposed aimed at achieving optimal vaccine benefit without interfering with disease activity status. Moreover, rare autoimmune adverse events related to vaccinations are discussed.

自身免疫性和自身炎症性风湿病 (ARD) 使用抗代谢物、钙调神经磷酸酶抑制剂和生物制剂治疗，或者中和细胞因子 [肿瘤坏死因子 (TNF)、白细胞介素 (IL)-1、IL-6、IL-17、B 细胞活化因子]或针对 B 细胞（抗 CD-20）、共刺激分子或 JAK 激酶。同样，对于流感或肺炎球菌疫苗，关于针对这一易感患者群体接种 SARS-CoV-2 感染和预防 COVID-19 的有效性的数据有限。此外，来自接种器官移植、炎症性肠病和结缔组织病患者的初步数据表明，在第一次接种疫苗后免疫原性有限，特别是在接受免疫抑制方案的患者中。在此提出了一套针对免疫抑制患者接种 SARS-CoV-2 疫苗的建议，旨在在不干扰疾病活动状态的情况下实现最佳疫苗效益。此外，还讨论了与疫苗接种相关的罕见自身免疫不良事件。